US Stock MarketDetailed Quotes

QLGN Qualigen Therapeutics

Watchlist
  • 0.3117
  • +0.0143+4.81%
Close Apr 18 16:00 ET
  • 0.3076
  • -0.0041-1.32%
Post 19:59 ET
1.97MMarket Cap-117P/E (TTM)

About Qualigen Therapeutics Company

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Company Profile

SymbolQLGN
Company NameQualigen Therapeutics
Listing DateJun 24, 2015
Issue Price5.00
Founded2004
CEOMr. Michael S. Poirier
MarketNASDAQ
Employees4
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address5857 Owens Avenue,Suite 300
CityCarlsbad
ProvinceCalifornia
CountryUnited States of America
Zip Code92008

Company Executives

  • Name
  • Position
  • Salary
  • Michael S. Poirier
  • Chairman of the Board and Chief Executive Officer
  • 728.45K
  • Christopher L. Lotz
  • Vice President, Finance, Chief Financial Officer and Chief Accounting Officer
  • 194.00K
  • Ira E. Ritter
  • Independent Director
  • 95.50K
  • Kurt H. Kruger
  • Independent Director
  • 69.66K
  • Sidney W Emery, Jr
  • Independent Director
  • 77.79K
  • Matthew Korenberg
  • Independent Director
  • 72.37K
  • Dr. Richard A. David
  • Independent Director
  • 69.66K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg